SYSTOLIC heart failure treatment Entresto (sacubitril/valsartan) has been listed on the Pharmaceutical Benefits Scheme (PBS) from 01 June.
Novartis said it would focus on providing doctors with education for appropriate use of Entresto.
The above article was sent to subscribers in Pharmacy Daily's issue from 10 May 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 10 May 17
